LOS ANGELES…April 14, 2021 – MedVector announces that it has appointed John Neal, founder and chairman of PCRS Network, as strategic advisor, pharma relations and clinical protocol. MedVector partners with clinical research organizations (CROs), sponsors, and patient recruitment companies to expand subject participation beyond existing clinical trial sites, and reach diverse populations to fill and complete studies faster.
Neal is an acknowledged industry leader, and brings extensive relationships in pharma, CROs, and clinical research sites to his role at MedVector.
“Data is useless if you can’t access the patient,” says Neal. “Now that we’ve seen what telemedicine can do, the clinical trials industry is ready for MedVector’s innovative technology, which connects patients at local providers with investigators at existing clinical trial sites. This means participants are no longer geographically limited. MedVector can land its device in front of any patient, regardless of their location or economic status. This opens up many possibilities to solve diversity and enrollment issues within current protocols.”
“John is an excellent addition to our team,” says MedVector Co-Founder and Chief Executive Officer Scott Stout. “His depth of experience, and strong industry relationships, will guide us to the next level as we build partnerships and add value to the clinical trial process, while strictly maintaining the same good clinical practice (GCP) as a traditional clinical trial appointment.”
Neal is a former chair and member of the board of trustees for the Association of Clinical Research Professionals (ACRP), an Arlington, VA-based non-profit organization that supports clinical research professionals through membership, training and development, and certification. Its more than 13,000 members work in clinical research in more than 70 countries. He is also a sought after contributor to industry publications and a frequent speaker at industry events.
MedVector has developed a clinical trial platform that expands participation beyond existing clinical trial sites, giving CROs access to millions of diverse subjects without triggering new sites. MedVector’s Prime-Control technology extends the reach of PIs to include patients at non-participating physician’s offices, and those who reside in inner cities and rural communities. The proprietary platform works within current protocols, and enables pharma sponsors to bring medications to market more quickly. With MedVector, no patient is too far away, or left behind. MedVector is headquartered in El Segundo, California. For more information, visit us at www.MedVector.com. Follow us on: Facebook | Linkedin | Twitter